Healthcare

Addiction Biotech Cannabis Genetics Healthcare Medical Devices Pharmaceutical Science Veterinary
News Release Digital Asset Direct

Jeffrey P. Halperin Joins AmeriLife as Chief Risk and Compliance Officer

AmeriLife

AmeriLife Group, LLC (“AmeriLife”), a national leader in developing, marketing, and distributing life and health insurance, annuities, and retirement planning solutions, announced today that Jeffrey P. Halperin has joined the company as its new Chief Risk and Compliance Officer (CRCO). Reporting to AmeriLife’s Chief Legal and Administrative Officer, Nathan Hightower, Halperin will oversee the company’s Compliance Department and lead an enterprise-wide approach to identifying, assessing and mitigating risks that the company may face to ensure that AmeriLife has the proper controls in place to achieve its business objectives. “We’re thrilled to welcome Jeff to AmeriLife and excited to add someone of his caliber to our organization,” said Hightower. “The need for a modern, best-in-class approach to corporate compliance and risk management has never been higher. Under Jeff’s leadership, I’m confident that he’ll continue to build and enhance our services to support the evolving needs of our company and partners.” Halperin comes to AmeriLife from Brighthouse Financial, the spinoff of MetLife’s former Retail Division, where he served as Chief Compliance Officer and Associate General Counsel, since 2017. In this role, he was responsible for managing Brighthouse Financial’s Compliance Department, which was charged with mitigating regulatory risk for the company. He also led the company’s Distribution and Vendor Contracts legal functions, Procurement, and Third-Party Risk Management. Prior to Brighthouse Financial, Halperin worked for nearly 20 years within MetLife’s Corporate Ethics & Compliance Department in a variety of roles, including as MetLife’s Global Money Laundering Prevention Officer; CCO of the MetLife Funds, MetLife Advisers, and MetLife Securities; and Senior Vice President of Compliance for MetLife’s U.S. Businesses. For more than 30 years, Halperin has been an active participant in the industry, serving on various industry committees and speaking at numerous industry conferences on topics related to securities and insurance regulation. Halperin, who will be based at AmeriLife’s Clearwater, Fla., headquarters, is a graduate of the University of Michigan and the University of Connecticut School of Law. “I am very excited to be joining AmeriLife at a time of impressive sales growth,” said Halperin. “I look forward to bringing my metrics-driven, process-oriented approach to the Risk and Compliance functions, so my team can help ensure that AmeriLife achieves its goals in a risk-aware and legally-compliant manner.” ### About AmeriLife AmeriLife’s strength is its mission: to provide insurance and retirement solutions to help people live longer, healthier lives. In doing so, AmeriLife has become recognized as an industry leader in developing, marketing and distributing life and health insurance, annuities, and retirement planning solutions to enhance the lives of pre-retirees and retirees across the United States. For more than 50 years, AmeriLife has partnered with top insurance carriers to provide value and quality to customers served through a national distribution network of over 300,000 agents and financial professionals and more than 120 marketing organizations and insurance agencies. For more information, visit AmeriLife.com, and follow AmeriLife on Facebook and LinkedIn. Contact Details Media Jeff Maldonado +1 321-297-1112 jmaldonado@amerilife.com Partnership Inquiries Patrick Nichols +1 727-726-0726 pnichols@amerilife.com Company Website https://amerilife.com/

September 14, 2023 09:00 AM Eastern Daylight Time

The Cultivated B Initiated Pre-Submission Process towards EFSA Certification for Cultivated Sausage

The Cultivated B

The Cultivated B (TCB) began discussions with the European Food Safety Authority (EFSA) and officially entered the pre-submission proces s for novel food approval of a novel or non-farmed sausage product. Subsequent to the official submission, TCB will emerge as world’s first biotech company to apply for EFSA certification for cultivated meat. This is a pivotal first step in the evolution of the cultivated meat market and establishes a viable path towards large-scale commercial production. “EFSA's Novel Food regulatory approvals process is among the most robust in the world, including a thorough and evidence-based assessment of food safety and nutritional value. For cultivated meat to become available in Europe, where this food was born, would mark a paradigm shift for the sector,” said Seth Roberts, policy manager at the Good Food Institute Europe. One of the most significant challenges in the cultivated meat sector is achieving production at the enormous volumes required by the food producer industry. In addition, food safety concerns and regulatory compliance further hinder cultivated meat from reaching consumers. TCB's early engagement with EFSA is a testament to knocking down these barriers, propelling the industry to democratize cultivated meat for the masses without compromising on quality or sustainability. "This is more than just a certification process; it’s a testament to our advanced, industrial-scale cellular agriculture technology and also a reflection of our unwavering commitment to usher in a new era of food production—one where health, taste, ethics and sustainability converge seamlessly,” said TCB CEO Dr. Hamid Noori. “The European cultivated meat sector has vast potential and considerable opportunity for growth. As this market gains prominence, our objective is to ensure consistent access to high-quality, sustainable meat for everyone. Attaining EFSA certification is a significant step in this direction.” The cell-based sausage product for which TCB seeks EFSA certification is similar to boiled sausages used in hot dogs and has been developed in close collaboration with TCB sister company The Family Butchers. It is a hybrid sausage product composed of vegan ingredients, including significant amounts of cultivated meat. Leveraging the combined expertise of both entities ensures that consumers will experience the familiar, delectable taste they love, all while benefiting from a sustainable and ethically produced product. EFSA certification is governed by a strict regulatory framework which emphasizes food safety standards. Achieving certification by EFSA for TCB’s cultivated sausage will indicate the safety of its cultivated meat products as measured by the highest European standards. It also charts the course and lays the groundwork for regulatory approvals worldwide. This strategic roadmap underscores the company’s determination to lead in the global cultivated meat industry, giving hundreds of startups in this space a path toward viable and scalable commercialization, setting new standards in food safety, innovation, and accessibility. About The Cultivated B (TCB) The Cultivated B’s multinational team of scientists develops and applies breakthrough technologies in cellular agriculture, precision fermentation and advanced bioreactor technology to enable scalable commercialization of the cellular-agriculture industry. TCB serves startups, corporations and academic research institutions within the food, pharma, cosmetics and personal care industries. With its pioneering engineering and production capabilities, TCB enables other companies to produce alternative proteins, such as cultivated meat, at industrial scale. The company’s fundamental commitment to minimizing the natural resources used paves the way toward a sustainable future, locally, regionally and globally. TCB’s research and development team is based in Germany, with manufacturing and an innovation hub based in Canada’s Toronto region. For more information, visit https://www.thecultivatedb.com and follow the company on LinkedIn. Contact Details Rainier Communications Jenna Beaucage +1 508-340-6851 tcb@rainerco.com Company Website https://www.thecultivatedb.com

September 14, 2023 08:06 AM Eastern Daylight Time

MVision AI Is Selected To Provide Its Contour+ Solution By The Republic Of Ireland’s Health Service Executive (HSE) For Its First Installation In The Country

MVision AI

MVision AI is experiencing ongoing and rapid growth within the health service sector globally. The company is delighted to announce that we have successfully been awarded the tender from the Republic of Ireland’s Health Service Executive (HSE) for the installation of our Contour+ auto contouring solution at Cork University Hospital. "MVision AI are truly delighted to have been selected as the preferred supplier of an AI auto contouring system to Cork University Hospital. This will be the first deployment of our Guideline Based Contour+ solution via our Cloud service within this country," says Stewart Pegrum, MVision AI's Vice President of Global Sales. The procurement was undertaken via a national EU tender process, which was published on 3rd February 2023 Each tender applicant was evaluated on Qualitative Selection Criteria including; Economic and Financial Standing, Technical and Professional Ability and Quality Assurance Standards. Tenders that achieve the minimum requirements set out in the Qualitative Selection Criteria were then evaluated to determine which presented the most economically advantageous tender using the award criteria below: Project Management & Installation (5%) Primary Requirements (5%) Functional Requirements (10%) Clinical Requirements (25%) ICT Technical Requirements (10%) Service & Support (5%) Training & Documentation (5%) Sustainability (5%) Cost (30%) As part of the clinical requirements sample delineations for a selection of structures were requested for evaluation purposes from the Tenderers. These were reviewed by the tender panel that was made up of Medical Physicists, Radiation Oncologists, Radiation therapists and HSE procurement representatives. " We recently started SABR Lung treatments and expect to introduce SABR Liver and SRS treatments in the near future. We hope MVision will help us to standardize contouring in line with best practice guidelines and reduce the time spent delineating patient datasets by approximately 50%, " says Mr. Michael Roche, Principal Physicist, Medical Physics Department in Cork University Hospital. MVision AI's interests in the UK and Ireland are represented by our longstanding distributor, Xiel, which specializes in providing solutions for Nuclear Medicine, Radiotherapy, and Diagnostic Radiology. "We are delighted that CUH have selected MVision AI as their solution for auto contouring, this was a very stringent process with much interaction and this award demonstrates the robust capabilities of Contour +", says Phil Neale, Xiel's Key Account Consultant in Radiotherapy Physics. About MVision AI MVision AI is an innovative software service provider for radiotherapy treatment planning. Our AI-powered automatic segmentation tool, Contour+, helps to standardize contouring and automate segmentation to streamline the radiotherapy treatment planning workflow. MVision AI is the AI-powered radiotherapy planning solution for treating cancer; MVision AI uses artificial intelligence to automate cancer treatment planning with its unique guideline-based AI contouring - Contour+; MVision AI announced the new guideline-based automatic segmentation service Contour+ release version 1.2.4 [1]; MVision AI's Contour+ has been officially recommended by NICE (National Institute for Health and Care Excellence) for use within the NHS, alongside several other AI auto-contouring tools[2]; MVision AI process a staggering 2750 scans per month, translating to nearly a quarter of all radiotherapy patients in the UK benefiting from Contour+; The next-generation technology speeds up the entire cancer treatment process, significantly reducing treatment planning time from weeks to days; According to information from the Irish Cancer Society, cancer is the leading cause of death in Ireland: an estimated 44,000 people in Ireland are diagnosed with cancer each year [3]; The scalable platform enables the improvement of cancer treatments worldwide. Contour+ has already been used in treating over 170,000 cancer patients in 16 countries. MVision.ai - Press Release: MVision AI launches Contour+ auto-contouring to facilitate standardization and shorten time to treatment for cancer radiotherapy MVision.ai - Exciting News: AI Auto-Contouring Recommended by NICE for Radiotherapy in the NHS! Irish Cancer Society - Cancer statistics MVision.ai MVision AI Linkedin page MVision AI Media Kit Interview requests: Alena Kruhlova alena.kruhlova@mvision.ai About Cork University Hospital (CUH) Currently Cork University Hospital (CUH) treats c.2000 patients annually. At present, the majority of volume delineation is a time-consuming process and is manually performed by CUH's 7 Consultant Radiation Oncologists who may be assisted at times by other staff members including Dosimetrists or Radiation Therapists. A new radiotherapy facility was opened in 2019. CUH.hse.ie Cork University Hospitals Linkedin Group About Xiel. Xiel is a specialist distributor of medical technologies in the UK and Ireland. We work with global leading solution providers; therefore, continuously improving efficiency and quality for our customers. Our partners research and develop highly specific products for what is often a small world market. The expertise of Xiel lies in our deep understanding of the structure and organisation of radiotherapy departments in the UK and Ireland, for us to advise on the best solutions possible. Xiel. Exceptional Products. Extraordinary Service. Everyday. Xiel.co.uk Xiel Linkedin page Contact Details MVision AI Alena Kruhlova alena.kruhlova@mvision.ai Company Website https://www.mvision.ai/

September 14, 2023 07:17 AM Eastern Daylight Time

Image

News Release

Principal Technologies laser focussed on acquiring healthcare tech to launch in North America

Principal Technologies

Jerry Trent, CEO of Principal Technologies joined Steve Darling from Proactive to share insights in a recent interview about the company's focus on healthcare technology companies in Europe. The company aims to identify local champions with exceptional healthcare technologies that are often limited to specific regions. Principal Technologies plans to leverage its access to these opportunities, helping them expand globally and bridge valuation gaps between European assets and the North American market. The company's strategic focus includes businesses with proven technologies and databases of patient information. The goal is to create a conglomerate of participations with synergies to benefit patients and shareholders. Principal Technologies has also acquired a clinical research organization (to facilitate efficient international distribution rights for healthcare tech companies while expanding its database. Trent mentioned that they are actively exploring significant acquisitions in line with their criteria, signaling exciting growth prospects for Principal Technologies in the coming months. The interview revealed the company's commitment to improving healthcare globally, driven by a seasoned team and guided by Liechtenstein's Prince, offering a promising future for the company and its stakeholders. Stay tuned for more updates on Principal Technologies' developments. Contact Details Proactive Investors +1 604-688-8158 na-editorial@proactiveinvestors.com

September 13, 2023 02:00 PM Eastern Daylight Time

Video

News Release

Rakovina Therapeutics continues to make progress as company provides corporate update

Rakovina Therapeutics Inc

Rakovina Therapeutics Executive Chairman Jeffery Bacha joined Steve Darling from Proactive to discuss the company's corporate highlights as part of its second-quarter financial report. Bacha highlighted several significant developments for the company during this period: including a publication in the Journal of Clinical Oncology. Rakovina Therapeutics published a paper in the Journal of Clinical Oncology describing pre-clinical data for its lead pre-clinical candidate, kt-3283. This data demonstrates the potential of kt-3283 to treat cancers that are resistant to first-generation PARP inhibitors. This development is crucial as it suggests that Rakovina's compound could address unmet medical needs in the treatment of various treatment-resistant cancers, including Ewing sarcoma. Bacha also said the company presented at the American Association of Cancer Research. The company presented new preclinical in vitro and in vivo data at the annual meeting of the American Association of Cancer Research. This data demonstrated the potential of Rakovina's kt-3000 series in treating treatment-resistant Ewing sarcoma, a rare childhood tumor. The kt-3000 series is a novel class of DNA-damage response inhibitors designed to selectively inhibit two important anti-cancer targets: poly(ADP) ribose polymerase (PARP) and histone deacetylase (HDAC). These developments reflect Rakovina Therapeutics' commitment to advancing innovative treatments for challenging and resistant cancers. The company's research and progress in the field of cancer therapy offer hope for patients and represent significant strides in addressing unmet medical needs. Contact Details Proactive Investors +1 604-688-8158 na-editorial@proactiveinvestors.com

September 13, 2023 01:30 PM Eastern Daylight Time

Video

xCures Platform advances progress on the White House Cancer Moonshot mission to end cancer as we know it.

xCures

xCures, a leader in data-driven cancer solutions, is thrilled to announce that its platform has been highlighted as a new commitment to deliver progress on the White House Cancer Moonshot mission – ending cancer as we know it. The xCures health-data technology platform has been designed to overcome a key challenge for many rare diseases: collecting, organizing, and standardizing comprehensive data from patients across the US. In alignment with the Cancer Moonshot Initiative’s goals to reduce cancer death rates by 50% over the next 25 years, xCures is launching an ambispective natural history study of DMG and DIPG. This study will speed up the identification of patterns that can inform more personalized treatment plans and targeted therapies. xCures will provide access without licensing fees to the data for academic and government researchers. Open access to this valuable resource will accelerate scientific breakthroughs and foster a community actively seeking a cure. “We recognize that collaboration is key to success. Our pledge extends to fostering an ongoing relationship with all stakeholders - patients, families, physicians, researchers, and advocacy organizations,” said Mika Newton, CEO of xCures. “Together, we can create a powerful collective dedicated to advancing the understanding and treatment of DMG DIPG.” DMG and DIPG patients are encouraged to sign up for the study at www.xcures.com/dmg About xCures xCures Inc. operates an AI-assisted platform that automatically retrieves medical records from all sites of care. The (unstructured) data is aggregated and organized into a powerful, always up-to-date care summary that helps cancer patients get the right therapy at the right time. The platform's portals, xINFORM for patients and xDECIDE for providers, facilitate treatment option decisions. The research portal, xUTILITY, generates Real-time, Regulatory-grade, Clinical data (RRC) for studies and decentralized trials. For more information, contact info@xcures.com or visit http://www.xcures.com. Contact Details xCures Inc Patrick van der Valk pvandervalk@xcures.com Company Website https://xcures.com

September 13, 2023 01:04 PM Eastern Daylight Time

Microban launches Ascera™: a patent-pending, cutting-edge antimicrobial technology inspired by nature

Microban International

Microban International is pleased to introduce its latest ground-breaking technology – Ascera™. This patent-pending, next generation antimicrobial technology uses an active ingredient inspired by nature*, and is designed for use in olefinic polymers and solvent-based coatings. Ascera is sustainable, metal free and less toxic than alternative technologies, and provides the lifelong antimicrobial product protection that Microban is known for around the world. As the global leader in antimicrobial and odor-control technologies, Microban is committed to the development of solutions that support product sustainability by extending their useful lifetimes. Ascera exemplifies the company’s commitment to sustainability by offering lasting product protection while maintaining critical attributes, such as ease of incorporation, safe handling, and good chemical, thermal and UV stability. Ascera will perform for the product’s expected lifetime when applied according to Microban’s standards, effectively inhibiting the growth of odor-causing bacteria to prevent stains and premature aging of the finished product. “Microban has always led the antimicrobial industry with technological innovations that contribute to product sustainability,” said Dr. Souvik Nandi, Vice President of R&D at Microban International. “In the past decade, regulatory and environmental groups have put increasing pressure on many of the antimicrobial chemistries that are currently used. As a result, Microban has invested significant resources in identifying naturally occurring solutions that are more sustainable and effective. We are very proud to roll out Ascera, which represents the culmination of many years of intensive research. This is the first of an exciting series of nature-inspired solutions that we will be launching in the next few years for different market segments and material types.” “As the global leader in antimicrobial, odor-control and surface modification solutions, Microban is always standing at the forefront of the industry. As we work towards our vision of becoming the most trusted brand in ultimate cleanliness and product protection, we want the world to rely on Microban for best-in-class solutions.” Michael Ruby, President of Microban International, said. “Our R&D teams are laser-focused on developing a range of cutting-edge technologies that are nature inspired for the different market sectors we serve. Our partners look to us first for what is next. Ascera will help leading brands to create clean, odor-free and high value end-use products, which their customers will choose to support sustainability and live a clean and refreshing lifestyle." Ascera is available to manufacturers in the U.S. and Asia, along with Microban’s support and expertise. Find out more at https://www.microban.com/antimicrobial-solutions/technologies/ascera and get in touch with a representative today! *The Microban ® technology used in this product is similar to acids found in nature and is used in multiple consumer product applications. Contact Details Audrey Jestin at kdm communications limited, St Neots, UK +44 1480 405333 ideas@kdm-communications.com Company Website https://www.microban.com/

September 13, 2023 10:00 AM Eastern Daylight Time

Image

Microban launches Ascera™: a patent-pending, cutting-edge antimicrobial technology inspired by nature

Microban International

Microban International is pleased to introduce its latest ground-breaking technology – Ascera™. This patent-pending, next generation antimicrobial technology uses an active ingredient inspired by nature*, and is designed for use in olefinic polymers and solvent-based coatings. Ascera is sustainable, metal free and less toxic than alternative technologies, and provides the lifelong antimicrobial product protection that Microban is known for around the world. As the global leader in antimicrobial and odor-control technologies, Microban is committed to the development of solutions that support product sustainability by extending their useful lifetimes. Ascera exemplifies the company’s commitment to sustainability by offering lasting product protection while maintaining critical attributes, such as ease of incorporation, safe handling, and good chemical, thermal and UV stability. Ascera will perform for the product’s expected lifetime when applied according to Microban’s standards, effectively inhibiting the growth of odor-causing bacteria to prevent stains and premature aging of the finished product. “Microban has always led the antimicrobial industry with technological innovations that contribute to product sustainability,” said Dr. Souvik Nandi, Vice President of R&D at Microban International. “In the past decade, regulatory and environmental groups have put increasing pressure on many of the antimicrobial chemistries that are currently used. As a result, Microban has invested significant resources in identifying naturally occurring solutions that are more sustainable and effective. We are very proud to roll out Ascera, which represents the culmination of many years of intensive research. This is the first of an exciting series of nature-inspired solutions that we will be launching in the next few years for different market segments and material types.” “As the global leader in antimicrobial, odor-control and surface modification solutions, Microban is always standing at the forefront of the industry. As we work towards our vision of becoming the most trusted brand in ultimate cleanliness and product protection, we want the world to rely on Microban for best-in-class solutions.” Michael Ruby, President of Microban International, said. “Our R&D teams are laser-focused on developing a range of cutting-edge technologies that are nature inspired for the different market sectors we serve. Our partners look to us first for what is next. Ascera will help leading brands to create clean, odor-free and high value end-use products, which their customers will choose to support sustainability and live a clean and refreshing lifestyle." Ascera is available to manufacturers in the U.S. and Asia, along with Microban’s support and expertise. Find out more at https://www.microban.com/antimicrobial-solutions/technologies/ascera and get in touch with a representative today! *The Microban® technology used in this product is similar to acids found in nature and is used in multiple consumer product applications Contact Details Audrey Jestin at kdm communications limited, St Neots, UK +44 1480 405333 ideas@kdm-communications.com Company Website https://www.microban.com/

September 13, 2023 10:00 AM Eastern Daylight Time

Poolbeg Pharma "moving forward rapidly" with POLB001

Poolbeg Pharma PLC

Poolbeg Pharma PLC (AIM:POLB, OTCQB:POLBF) CEO Jeremy Skillington speaks to Thomas Warner from Proactive after announcing the pharma & biotech's interim results for the six months to 30 June 2023. Skillington highlights Poolbeg's "healthy" financial position and attributes it to low operational cash burn and strong financial discipline. Skillington also emphasises cost-effective R&D, citing examples like the LPS challenge study and AI programs that utilise supercomputers for efficiency. They continue to seek non-diluted funding opportunities to support infectious disease programs, following a €2.3 million grant from the Irish government in 2022 for an oral vaccine program. Operational achievements include positive results from a POLB001 LPS human challenge trial, showing potential in treating acute inflammatory conditions and oncology-related issues. The company's collaboration with CytoReason identified valuable drug targets for influenza treatment. Additionally, progress was noted in oral vaccine delivery and clinical trials for an oral GLP-1 agonist. Skillington hinted at new indications for POLB001 in the oncology sector, addressing cytokine release syndrome, a significant market opportunity. Future milestones include RSV dataset validation, oral vaccine encapsulation, and influenza drug target validation. The company remains focused on clinical trial preparations and partnerships with pharmaceutical companies, reflecting a proactive approach to advancing their programs. Contact Details Proactive UK Ltd +44 20 7989 0813 uk@proactiveinvestors.com

September 13, 2023 08:58 AM Eastern Daylight Time

Video

1 ... 91 92 93 94 95 ... 302